Drug Profile


Alternative Names: Maleate salt of T 817; T-817 MA

Latest Information Update: 02 Jun 2017

Price : $50

At a glance

  • Originator Toyama Chemical
  • Class Antidementias; Neuroprotectants; Small molecules
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 05 May 2017 Toyama Chemical completes a phase II trial for Alzheimer's disease in the US (NCT02079909)
  • 01 Feb 2016 Toyama Chemical initiates a phase I pharmacokinetic trial in subjects with hepatic impairment and healthy subjects in USA (NCT02693197)
  • 26 Jan 2016 Toyama Chemical plans a phase I pharmacokinetic trial in Volunteers in USA (NCT02693197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top